Paolo Emanuele Levi-Setti1,2, Luciano Negri3, Annamaria Baggiani3, Emanuela Morenghi4, Elena Albani3, Valentina Parini3, Luca Cafaro3, Carola Maria Conca Dioguardi3, Amalia Cesana3, Antonella Smeraldi3, Armando Santoro5. 1. Humanitas Fertility Centre, Department of Gynaecology, Division of Gynaecology and Reproductive Medicine, Humanitas Research Hospital, Rozzano, (Milan), Italy. paolo.levi_setti@humanitas.it. 2. Department of Obstetrics, Gynaecology and Reproductive Sciences, Yale University, School of Medicine, New Haven, CT, USA. paolo.levi_setti@humanitas.it. 3. Humanitas Fertility Centre, Department of Gynaecology, Division of Gynaecology and Reproductive Medicine, Humanitas Research Hospital, Rozzano, (Milan), Italy. 4. Biostatistics Unit, Humanitas Research Hospital, Rozzano, (Milan), Italy. 5. Department of Medical Oncology & Hematology, Humanitas Research Hospital, Rozzano, (Milan), Italy.
Abstract
PURPOSE: To analyse the impact of female characteristics on assisted reproductive technology outcome among male haematological cancer survivors. METHODS: A retrospective analysis of 93 haematological cancer survivors attending our tertiary referral fertility centre between June 1998 and June 2017 for achieving fatherhood with assisted reproductive technology treatments. RESULTS: A progressive increase in the median female age was observed during the study period (32.2 years until the year 2007 and 36.9 years from the year 2012). Fifty-five out of 93 patients were treated with intracytoplasmic sperm injection (ICSI) (113 ovarian stimulations, 108 ICSI procedures). Cryopreserved ejaculated sperm was used in 28 couples, fresh sperm in 19, and thawed testicular sperm in 8 couples. Mean female age at ovarian stimulation was 37.0 ± 4.7 years. Twenty-six pregnancies resulted in a full-term birth (23% per started ovarian stimulation; 43.6% per couple) and 33 children were born. No significant differences were observed according to source of sperm (fresh, frozen, testicular) and multivariate analysis confirmed that maternal age was the only variable inversely related to the cumulative delivery rate, being five times lower (15.7%) when the female partner was ≥ 40 years (OR = 0.22, 95% CI 0.06-0.77) vs. 58.3% with younger women (p = 0.0037). CONCLUSIONS: Delayed childbearing and female ageing affect ICSI outcome in couples where the male is a survivor of haematological cancer. This topic should be discussed when counselling male cancer patients about fertility preservation.
PURPOSE: To analyse the impact of female characteristics on assisted reproductive technology outcome among male haematological cancer survivors. METHODS: A retrospective analysis of 93 haematological cancer survivors attending our tertiary referral fertility centre between June 1998 and June 2017 for achieving fatherhood with assisted reproductive technology treatments. RESULTS: A progressive increase in the median female age was observed during the study period (32.2 years until the year 2007 and 36.9 years from the year 2012). Fifty-five out of 93 patients were treated with intracytoplasmic sperm injection (ICSI) (113 ovarian stimulations, 108 ICSI procedures). Cryopreserved ejaculated sperm was used in 28 couples, fresh sperm in 19, and thawed testicular sperm in 8 couples. Mean female age at ovarian stimulation was 37.0 ± 4.7 years. Twenty-six pregnancies resulted in a full-term birth (23% per started ovarian stimulation; 43.6% per couple) and 33 children were born. No significant differences were observed according to source of sperm (fresh, frozen, testicular) and multivariate analysis confirmed that maternal age was the only variable inversely related to the cumulative delivery rate, being five times lower (15.7%) when the female partner was ≥ 40 years (OR = 0.22, 95% CI 0.06-0.77) vs. 58.3% with younger women (p = 0.0037). CONCLUSIONS: Delayed childbearing and female ageing affect ICSI outcome in couples where the male is a survivor of haematological cancer. This topic should be discussed when counselling male cancerpatients about fertility preservation.
Authors: P Anserini; S Chiodi; S Spinelli; M Costa; N Conte; F Copello; A Bacigalupo Journal: Bone Marrow Transplant Date: 2002-10 Impact factor: 5.483
Authors: James M Hotaling; Natalya A Lopushnyan; Michael Davenport; Heather Christensen; Erin R Pagel; Charles H Muller; Thomas J Walsh Journal: Fertil Steril Date: 2012-10-25 Impact factor: 7.329
Authors: A La Marca; G Sighinolfi; D Radi; C Argento; E Baraldi; A Carducci Artenisio; G Stabile; A Volpe Journal: Hum Reprod Update Date: 2009-09-30 Impact factor: 15.610
Authors: P E Levi Setti; E Albani; M Matteo; E Morenghi; E Zannoni; A M Baggiani; V Arfuso; P Patrizio Journal: Hum Reprod Date: 2012-11-21 Impact factor: 6.918